Patent Number: 8,574,573

Title: Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders

Abstract: The present invention relates to antibodies that specifically bind to IL12R.beta.1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN.gamma. production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN.gamma. production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Inventors: Carballido Herrera; Jose M. (Allschwil, CH), Hartle; Stefan (Jesenwang, DE), Heusser; Christoph (Oberwil, CH), Klagge; Ingo (Neuried, DE), Polzer; Andrea (Munchen, DE), Schwaerzler; Christoph (St Louis, FR), Wochnik-Veltrup; Gabriela (Eching a.A, DE)

Assignee: Novartis AG

International Classification: A61K 39/395 (20060101); C07K 16/28 (20060101)

Expiration Date: 1/05/12017